Ellsworth Advisors LLC Invests $734,000 in Electromed, Inc. (NYSE:ELMD)

Ellsworth Advisors LLC acquired a new stake in shares of Electromed, Inc. (NYSE:ELMD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 24,834 shares of the company’s stock, valued at approximately $734,000.

A number of other large investors also recently bought and sold shares of ELMD. Renaissance Technologies LLC increased its holdings in shares of Electromed by 4.8% in the 2nd quarter. Renaissance Technologies LLC now owns 103,004 shares of the company’s stock valued at $1,548,000 after acquiring an additional 4,736 shares during the period. Gabelli Funds LLC grew its stake in Electromed by 7.8% in the second quarter. Gabelli Funds LLC now owns 38,675 shares of the company’s stock valued at $581,000 after purchasing an additional 2,808 shares during the last quarter. Marshall Wace LLP bought a new position in Electromed in the second quarter worth about $256,000. Hunter Associates Investment Management LLC lifted its position in shares of Electromed by 12.3% during the third quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company’s stock valued at $2,199,000 after buying an additional 11,250 shares during the last quarter. Finally, Navellier & Associates Inc. bought a new stake in shares of Electromed in the 3rd quarter valued at about $368,000. Institutional investors own 40.82% of the company’s stock.

Electromed Trading Up 0.4 %

Shares of ELMD opened at $34.00 on Monday. The firm has a market cap of $287.57 million, a PE ratio of 47.22 and a beta of 0.31. Electromed, Inc. has a 12 month low of $9.90 and a 12 month high of $34.25. The stock has a fifty day moving average price of $29.57 and a 200-day moving average price of $22.32.

Electromed (NYSE:ELMD) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.13. The company had revenue of $14.67 million during the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.

Insider Buying and Selling

In other Electromed news, Director Andrew Summers sold 12,731 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $29.98, for a total transaction of $381,675.38. Following the sale, the director now owns 165,755 shares in the company, valued at approximately $4,969,334.90. The trade was a 7.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Electromed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 9th.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.